Litcius/Paper detail

Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice

Jiaqi Li, Zherui Zhang, Hongqing Zhang, Yanan Zhang, Xiang‐Yue Zeng, Qiu‐Yan Zhang, Cheng‐Lin Deng, Xiaodan Li, Bo Zhang, Han‐Qing Ye

2021Signal Transduction and Targeted Therapy34 citationsDOIOpen Access PDF

Abstract

The lung is the prophylaxis target against SARS-CoV-2 infection, and neutralizing antibodies are a leading class of biological products against various infectious viral pathogen. In this study, we develop a safe and cost-effective platform to express neutralizing antibody in the lung with replicating mRNA basing on alphavirus replicon particle (VRP) delivery system, to prevent SARS-CoV-2 infections. First, a modified VEEV replicon with two subgenomic (sg) promoters was engineered to translate the light and heavy chains of antibody simultaneously, for expression and assembly of neutralizing anti-SARS-CoV-2 antibody CB6. Second, the feasibility and protective efficacy of replicating mRNA against SARS-CoV-2 infection were demonstrated through both in vitro and in vivo assays. The lung target delivery with the help of VRP system resulted in efficiently block SARS-CoV-2 infection with reducing viral titer and less tissue damage in the lung of mice. Overall, our data suggests that expressing neutralizing antibodies in the lungs with the help of self-replicating mRNA could potentially be a promising prophylaxis approach against SARS-CoV-2 infection.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyNasal administrationCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakAntibodyNeutralizing antibodyMessenger RNABiologyMedicineImmunologyGeneVirusGeneticsPathologyInfectious disease (medical specialty)OutbreakDiseaseRNA Interference and Gene DeliverySARS-CoV-2 and COVID-19 ResearchVirus-based gene therapy research
Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice | Litcius